Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 2
1964 1
1966 1
1973 1
1974 1
1975 2
1978 1
1980 3
1981 1
1982 5
1983 9
1984 1
1985 4
1986 6
1987 16
1988 22
1989 10
1990 12
1991 14
1992 16
1993 26
1994 26
1995 36
1996 39
1997 43
1998 55
1999 59
2000 44
2001 63
2002 79
2003 94
2004 146
2005 168
2006 181
2007 247
2008 312
2009 336
2010 396
2011 470
2012 574
2013 700
2014 774
2015 844
2016 935
2017 1058
2018 1246
2019 1443
2020 1804
2021 402
Text availability
Article attribute
Article type
Publication date

Search Results

11,362 results
Results by year
Filters applied: . Clear all
Page 1
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. Verma V, et al. Among authors: fan y. Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23. Nat Immunol. 2021. PMID: 33230330
Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target.
Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporiciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Le X, et al. Among authors: fan yh. J Thorac Oncol. 2020 Dec 31:S1556-0864(20)31136-9. doi: 10.1016/j.jtho.2020.12.010. Online ahead of print. J Thorac Oncol. 2020. PMID: 33388477
Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19.
Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, Cheng J, Cui Y, Liu B, Dai M, Chen L, Han D, Fan Y, Zeng Y, Li W, Li S, Chen X, Shen M, Pan P; medical team from Xiangya Hospital to support Hubei, China. Zhang Y, et al. Among authors: fan y. Mol Cell Endocrinol. 2021 Feb 5;521:111097. doi: 10.1016/j.mce.2020.111097. Epub 2020 Dec 2. Mol Cell Endocrinol. 2021. PMID: 33278491 Free PMC article.
Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome.
Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, Sun D, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Rom O, et al. Among authors: fan y. Sci Transl Med. 2020 Dec 2;12(572):eaaz2841. doi: 10.1126/scitranslmed.aaz2841. Sci Transl Med. 2020. PMID: 33268508
Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study.
Shi N, Liu B, Liang N, Ma Y, Ge Y, Yi H, Wo H, Gu H, Kuang Y, Tang S, Zhao Y, Tong L, Liu S, Zhao C, Chen R, Bai W, Fan Y, Shi Z, Li L, Liu J, Gu H, Zhi Y, Wang Z, Li Y, Li H, Wang J, Jiao L, Tian Y, Xiong Y, Huo R, Zhang X, Bai J, Chen H, Chen L, Feng Q, Guo T, Hou Y, Hu G, Hu X, Hu Y, Huang J, Huang Q, Huang S, Ji L, Jin H, Lei X, Li C, Wu G, Li J, Li M, Li Q, Li X, Liu H, Liu J, Liu Z, Ma Y, Mao Y, Mo L, Na H, Wang J, Song F, Sun S, Wang D, Wang M, Wang X, Wang Y, Wang Y, Wu W, Wu L, Xiao Y, Xie H, Xu H, Xu S, Xue R, Yang C, Yang K, Yang P, Yuan S, Zhang G, Zhang J, Zhang L, Zhao S, Zhao W, Zheng K, Zhou Y, Zhu J, Zhu T, Li G, Wang W, Zhang H, Wang Y, Wang Y. Shi N, et al. Among authors: fan y. Pharmacol Res. 2020 Nov;161:105290. doi: 10.1016/j.phrs.2020.105290. Epub 2020 Nov 9. Pharmacol Res. 2020. PMID: 33181320 Free PMC article.
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J; CameL Study Group. Zhou C, et al. Among authors: fan y. Lancet Respir Med. 2020 Dec 18:S2213-2600(20)30365-9. doi: 10.1016/S2213-2600(20)30365-9. Online ahead of print. Lancet Respir Med. 2020. PMID: 33347829
11,362 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page